ISSN:
1569-8041
Keywords:
adjuvant chemotherapy
;
adrenocortical cancer
;
disease-free interval
;
o,p'DDD
;
streptozocin
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background:To evaluate the efficacy of streptozocin and o,p'DDD(SO) in adrenocortical cancer (ACC) patients since other chemotherapeuticregimens have limited effects. Patients and methods:We performed a phase II study with SOtherapy in 40 ACC patients (median age 44 years). Oral o,p'DDD administration(1–4 g/d, every day) was given together with intravenous streptozocin(1 g/d for five days, thereafter 2 g once every three weeks).5HT3-receptor blocker was used as standard premedication forstreptozocin. Results:The SO therapy was found to have significant effects ondisease-free interval (P= 0.02) as well as on survival (P=0.01) in adjuvantly treated cases (n= 17) in comparison to thepatients who did not get any therapy after complete resection (n=11). Complete or partial response was obtained in 36.4% of patientswith measurable disease (n= 22). The overall two-year and five-yearsurvival rates were 70% and 32.5%, respectively. The presenceof metastases at diagnosis was identified as a poor prognostic factor (P= 0.02). Conclusions:The present study necessitates further randomizedclinical study of SO therapy in the treatment of ACC, mainly as adjuvanttreatment immediately after curative intended surgery, and could be developedinto a regular treatment regimen.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008377915129
Permalink
